Patrick John Finn Sells 2,058 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,058 shares of the firm’s stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the transaction, the chief operating officer now directly owns 265,460 shares of the company’s stock, valued at $10,615,745.40. This represents a 0.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, April 2nd, Patrick John Finn sold 206 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total value of $7,978.38.
• On Monday, February 3rd, Patrick John Finn sold 2,845 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total value of $140,400.75.

Twist Bioscience Price Performance

NASDAQ TWST opened at $40.11 on Friday. Twist Bioscience Co. has a fifty-two week low of $30.32 and a fifty-two week high of $60.90. The stock’s 50-day moving average is $39.67 and its two-hundred day moving average is $44.27. The firm has a market cap of $2.39 billion, a P/E ratio of -11.87 and a beta of 2.34. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm’s revenue was up 24.1% compared to the same quarter last year. During the same period last year, the business earned ($0.75) EPS. On average, analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Several large investors have recently modified their holdings of TWST. Versant Capital Management Inc lifted its position in Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after acquiring an additional 580 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after purchasing an additional 303 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience during the 3rd quarter valued at approximately $34,000. Van ECK Associates Corp grew its holdings in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares during the last quarter. Finally, Banque Transatlantique SA bought a new position in Twist Bioscience in the 4th quarter worth approximately $43,000.

Analyst Upgrades and Downgrades

TWST has been the topic of several research analyst reports. Guggenheim set a $50.00 target price on Twist Bioscience in a research note on Friday, March 28th. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. JPMorgan Chase & Co. increased their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Finally, Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $52.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.